Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifeprunox Long-term Safety and Efficacy in Schizophrenia (Extension)
NCT00193713Phase 3Completed
- Sponsor
- Solvay
- Start
- May 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of bifeprunox in schizophrenia (2 arms), sponsored by Solvay. Primary endpoint: Safety and Tolerability (Adverse Events, Vital Signs, Laboratory Parameters). Started May 2005; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00193713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193713.